Evotec Historical Income Statement
| EVO Stock | USD 4.54 0.34 6.97% |
Historical analysis of Evotec SE income statement accounts such as Depreciation And Amortization of 159.5 K or Total Revenue of 820.5 M can show how well Evotec SE ADR performed in making a profits. Evaluating Evotec SE income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Evotec SE's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Evotec SE ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Evotec SE ADR is a good buy for the upcoming year.
Evotec |
About Evotec Income Statement Analysis
Evotec SE ADR Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Evotec SE shareholders. The income statement also shows Evotec investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Evotec SE Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Evotec SE ADR. It is also known as Evotec SE overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Evotec SE's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Evotec SE ADR current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At this time, Evotec SE's Research Development is very stable compared to the past year. As of the 27th of December 2024, Cost Of Revenue is likely to grow to about 636.7 M, though Operating Income is likely to grow to (101.7 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 618.0M | 751.4M | 781.4M | 820.5M | Depreciation And Amortization | 67.6M | 81.7M | 167.9K | 159.5K |
Evotec SE income statement Correlations
Click cells to compare fundamentals
Evotec SE Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evotec SE income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Operating Expenses | 371.9M | 449.2M | 576.4M | 730.6M | 888.5M | 932.9M | |
| Operating Income | 62.6M | 48.5M | 27.3M | 12.5M | (107.1M) | (101.7M) | |
| Ebit | 62.6M | 19.4M | 230.8M | (167.7M) | (7.3M) | (7.0M) | |
| Ebitda | 121.7M | 75.5M | 298.4M | (86.1M) | (7.2M) | (6.8M) | |
| Total Operating Expenses | 58.4M | 74.0M | 109.9M | 153.2M | 282.1M | 296.2M | |
| Net Income | 38.2M | 6.3M | 215.5M | (175.7M) | (83.9M) | (79.7M) | |
| Income Tax Expense | 19.3M | 19.6M | 21.5M | 21.7M | (40.7M) | (38.6M) | |
| Depreciation And Amortization | 59.1M | 56.1M | 67.6M | 81.7M | 167.9K | 159.5K | |
| Total Revenue | 446.4M | 500.9M | 618.0M | 751.4M | 781.4M | 820.5M | |
| Gross Profit | 132.9M | 125.7M | 151.5M | 174.1M | 175.1M | 183.8M | |
| Interest Expense | 7.5M | 8.5M | 9.3M | 13.2M | 11.7M | 12.3M | |
| Selling General Administrative | 66.5M | 77.2M | 96.0M | 142.7M | 152.7M | 160.4M | |
| Research Development | 58.4M | 63.9M | 72.2M | 76.6M | 112.5M | 118.2M | |
| Cost Of Revenue | 313.5M | 375.2M | 466.5M | 577.4M | 606.4M | 636.7M | |
| Income Before Tax | 56.6M | 25.8M | 237.0M | (154.0M) | (103.8M) | (98.6M) | |
| Total Other Income Expense Net | (6.0M) | (22.7M) | 196.0M | (174.8M) | 3.2M | 3.4M | |
| Tax Provision | 19.3M | 19.6M | 21.5M | 21.7M | 3.3M | 3.2M | |
| Net Interest Income | (5.2M) | (7.1M) | (7.0M) | (4.8M) | (2.5M) | (2.6M) | |
| Interest Income | 2.2M | 1.3M | 2.3M | 8.3M | 9.3M | 9.7M | |
| Net Income From Continuing Ops | 37.2M | 6.3M | 215.5M | (175.7M) | (83.9M) | (79.7M) | |
| Reconciled Depreciation | 48.8M | 56.1M | 70.4M | 81.7M | 93.0M | 63.2M | |
| Net Income Applicable To Common Shares | 84.2M | 38.1M | 6.3M | 215.5M | 247.8M | 260.2M |
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Stock
| 0.81 | ME | 23Andme Holding | PairCorr |
| 0.74 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | DRRX | Durect | PairCorr |
| 0.69 | DTIL | Precision BioSciences | PairCorr |
| 0.68 | DRMA | Dermata Therapeutics | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.50) | Revenue Per Share 2.1925 | Quarterly Revenue Growth (0.06) | Return On Assets (0.02) | Return On Equity (0.16) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.